Valerie Roudieres
Overview
Explore the profile of Valerie Roudieres including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cegarra C, Cameron B, Chaves C, Dabdoubi T, Do T, Genet B, et al.
PLoS One
. 2022 Sep;
17(9):e0274667.
PMID: 36108060
Background: Increasing brain exposure of biotherapeutics is key to success in central nervous system disease drug discovery. Accessing the brain parenchyma is especially difficult for large polar molecules such as...
2.
Lopez-Grancha M, Bernardelli P, Moindrot N, Genet E, Vincent C, Roudieres V, et al.
J Pharmacol Exp Ther
. 2021 Sep;
378(3):262-275.
PMID: 34531308
In Alzheimer disease (AD), the double-strand RNA-dependent kinase protein kinase R (PKR )/EIF2AK2 is activated in brain with increased phosphorylation of its substrate eukaryotic initiation factor 2 (eIF2). AD risk-promoting...
3.
Chaves C, Do T, Cegarra C, Roudieres V, Tolou S, Thill G, et al.
Pharmaceutics
. 2020 Oct;
12(10).
PMID: 33066641
The non-human primate (NHP)-brain endothelium constitutes an essential alternative to human in the prediction of molecule trafficking across the blood-brain barrier (BBB). This study presents a comparison between the NHP...
4.
Latta-Mahieu M, Elmer B, Bretteville A, Wang Y, Lopez-Grancha M, Goniot P, et al.
Glia
. 2017 Nov;
66(3):492-504.
PMID: 29134678
Chronic inflammation represents a central component in the pathogenesis of Alzheimer's disease (AD). Recent work suggests that breaking immune tolerance by Programmed cell Death-1 (PD1) checkpoint inhibition produces an IFN-γ-dependent...